Hookipa Pharma (HOOK) announced that an IND was cleared by the FDA so that it could begin its phase 1/2 study treating patients with Human Papilloma Virus ((HPV))-positive cancers. The reason why this latest development is important for the biotech is because it will be the first immuno-oncology program from the pipeline. As a catalyst, investors have data to look forward to approximately 1-year from now because Hookipa intends to release preliminary data in late 2020/early 2021. Another promising aspect is that this biotech has partnered with Gilead Sciences (GILD) to